Skip to main content

MECANISMOS MOLECULARES DEL CANCER UROLOGICO

RED2018-102769-T

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Redes Investigación /Redes Excelencia
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis

  • Shahrouzi, Parastoo
  • Astobiza, Ianire
  • Cortázar, Ana R.
  • Torrano, Verónica
  • Macchia, Alice
  • Flores, Juana María
  • Niespolo, Chiara
  • Mendizábal, Isabel
  • Caloto, Rubén
  • Ercilla, Amaia
  • Camacho, Laura
  • Arreal, Leire
  • Bizkarguenaga, Maider
  • Martínez-Chantar, María Luz
  • Bustelo, Xosé R.
  • Berra, Edurne
  • Kiss-Toth, Endre
  • Velasco, Guillermo
  • Zabala-Letona, Amaia
  • Carracedo, Arkaitz
© 2020 by the authors., Prostate cancer is the most frequent malignancy in European men and the second worldwide. One of the major oncogenic events in this disease includes amplification of the transcription factor cMYC. Amplification of this oncogene in chromosome 8q24 occurs concomitantly with the copy number increase in a subset of neighboring genes and regulatory elements, but their contribution to disease pathogenesis is poorly understood. Here we show that TRIB1 is among the most robustly upregulated coding genes within the 8q24 amplicon in prostate cancer. Moreover, we demonstrate that TRIB1 amplification and overexpression are frequent in this tumor type. Importantly, we find that, parallel to its amplification, TRIB1 transcription is controlled by cMYC. Mouse modeling and functional analysis revealed that aberrant TRIB1 expression is causal to prostate cancer pathogenesis. In sum, we provide unprecedented evidence for the regulation and function of TRIB1 in prostate cancer., We are grateful to the Carracedo lab for valuable input, to Ana M. Aransay and F. Elortza for technical advice. P.S. was funded by the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia, the Basque Department of Health (2016111109) and the MICINN RTI2018-097267-B-I00. A. Macchia was funded by a FPI predoctoral fellowship from MICINN (PRE2018-083607). EB is funded by the MICINN (BFU2016-76872-R (FEDER/EU), PID2019-108112RB-I00, Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2017-90794-REDT). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the BBVA foundation and the MICINN (SAF2016-79381-R (FEDER/EU; PID2019-108787RB-I00) Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2016-81975-REDT and RED2018-102769-T), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Starting Grant 336343, Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • Dietmann, Sabine
  • López, Judith
  • Morón-Calvente, Virginia
  • D'Ambrosi, Silvia
  • Nombela, Paz
  • Zamacola, Kepa
  • Mendizábal, Isabel
  • García-Longarte, Saioa
  • Zabala-Letona, Amaia
  • Astobiza, Ianire
  • Fernández, Sonia
  • Paniagua, Alejandro
  • Miguel-López, Borja
  • Marchand, Virginie
  • Alonso-López, Diego
  • Merkel, Angelika
  • García-Tuñón, Ignacio
  • Ugalde-Olano, Aitziber
  • Loizaga-Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Azkargorta, Mikel
  • Elortza, Félix
  • Bárcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Di Domenico, Tomás
  • Sánchez-Martín, Manuel A.
  • De Las Rivas, Javier
  • Guil, Sònia
  • Motorin, Yuri
  • Helm, Mark
  • Pandolfi, Pier Paolo
  • Carracedo, Arkaitz
  • Blanco, Sandra
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology., This work was funded by the Spanish Ministry of Science and Innovation MICINN/AEI/1013039/501100011033 and by “ERDF A way of making Europe”, by the “European Union” (SAF2016-78667-R and PID2019-111692RB-I00), MINECO (RYC-2014-16550), AECC (LABAE19040BLAN), Proteored-ISCIII, and Consejería de Educación de la Junta de Castilla y León (CSI264P20). R.G-V. was supported by MICINN/AEI/1013039/501100011033 and by “ESF Investing in your future” (BES-2017-080530). A.M.A-G. was supported by the USAL-Santander PhD fellowship. J.L-L. was supported by the AECC (PRDSA19002LÓPE) and MIU(FPU19/01190). B.M.L. was supported by Junta de Castilla y León ‐ Fondo Social Europeo (ESF). I.M. was supported by the Cris contra el cáncer grant PR_TPD_2020-19. The work of A. Carracedo is supported by the MICINN (PID2019-108787RB-I00 (FEDER/EU); Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded by FEDER funds and ISCIII. The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01)., Peer reviewed